Mammary Cell News Volume 15.48 | Dec 7 2023

December 7, 2023

2023-12-07 | MCN 15.48

Mammary Cell News by STEMCELL Technologies

Vol. 15.48 – 7 December, 2023

TOP STORY

B3GALT6 Promotes Dormant Breast Cancer Cell Survival and Recurrence by Enabling Heparan Sulfate-Mediated FGF Signaling

Scientists derived a dormancy-associated residual tumor cell signature that mirrored the transcriptional response to neoadjuvant therapy in patients and was enriched for extracellular matrix-related pathways.
[Cancer Cell]

Abstract Graphical Abstract

Scale up your cell isolation with Easy 250 EasySep™ magnet

PUBLICATIONSRanked by the impact factor of the journal

Targeting ABCA12-Controlled Ceramide Homeostasis Inhibits Breast Cancer Stem Cell Function and Chemoresistance

Investigators developed a stem cell factor SOX9-based reporter for isolating CSCs in primary tumors and metastases of spontaneous mammary tumor models.
[Science Advances]

Full Article

Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

The authors observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor olaparib.
[Cancer Research]

Abstract

IMPA2 Promotes Basal-Like Breast Cancer Aggressiveness by a MYC-Mediated Positive Feedback Loop

Researchers showed that in contrast to other subtypes, inositol monophosphatase 2 (IMPA2) was dramatically increased in basal-like breast cancer.
[Cancer Letters]

Full Article

Clonal Heterogeneity in ER+ Breast Cancer Reveals the Proteasome and PKC as Potential Therapeutic Targets

Scientists investigated the evolution and mechanistic heterogeneity in clonal populations of cell models for estrogen receptor (ER) positive breast cancer.
[npj Breast Cancer]

Full Article

Restoring microRNA-34a Overcomes Acquired Drug Resistance and Disease Progression in Human Breast Cancer Cell Lines via Suppressing the ABCC1 Gene

The authors investigated the beneficial role and mechanism of miRNA-34a-based gene therapy as a novel approach for conquering drug resistance mediated by ATP-binding cassette (ABC) transporters in breast cancer cells.
[Breast Cancer Research and Treatment]

Full Article

DPM2 Serve as Novel Oncogene and Prognostic Marker Transactivated by ESR1 in Breast Cancer

Researchers uncovered the tumorigenic and prognostic role of dolichyl-phosphate mannosyltransferase subunit 2 (DPM2) in breast cancer, cellular assays, and bioinformatics analysis highlighted DPM2 as oncogene via inhibited cancer-related signaling pathways in breast cancer.
[Environmental Toxicology]

Abstract

SOX10 Promotes the Malignant Biological Behavior of Basal-Like Breast Cancer Cells by Regulating EMT Process

The authors investigated the regulatory mechanisms and roles of SRY-box transcription factor 10 (SOX10) in basal-like breast cancer progression.
[Heliyon]

Full Article

Downregulation of BUBR1 Regulates the Proliferation and Cell Cycle of Breast Cancer Cells and Increases the Sensitivity of Cells to Cisplatin

Investigators showed that BUBR1 loss inhibited the phosphorylation of TAK1/JNK. In vitro and in vivo studies indicated the knockdown of BUBR1 rendered the breast cancer cells more sensitive to cisplatin.
[In Vitro Cellular & Developmental Biology – Animal]

Abstract

Learn how to avoid jargon and use blogs and social media channels to inform the public about your science

REVIEWS

The Adverse Outcome Pathway for Breast Cancer: A Knowledge Management Framework Bridging Biomedicine and Toxicology

Scientists review the current state of published knowledge with regard to breast cancer to identify relevant key mechanisms for inclusion into breast cancer adverse outcome pathways and to concurrently map non-animal methods addressing these key events.
[Discover Oncology]

Full Article

INDUSTRY AND POLICY NEWS

MiRaDor Trial Marks First-Ever Joint Effort by MEDSIR and Oncoclinicas & Co in Pioneering Breast Cancer Research

MEDSIR presented the design of the MiRaDor trial conducted in collaboration with Oncoclínicas & Co, which aims to evaluate the usefulness of ctDNA analysis to detect minimal residual disease in patients who had hormone receptor-positive/HER2-negative early breast cancer and are at high-risk of relapse.
[MEDSIR (PRNewswire)]

Press Release

FEATURED EVENT

Mammary Cell News Volume 15.48 | Dec 7 2023

B3GALT6 Promotes Dormant Breast Cancer Cell Survival and Recurrence by Enabling Heparan Sulfate-Mediated FGF Signaling

Targeting ABCA12-Controlled Ceramide Homeostasis Inhibits Breast Cancer Stem Cell Function and Chemoresistance

Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

IMPA2 Promotes Basal-Like Breast Cancer Aggressiveness by a MYC-Mediated Positive Feedback Loop

Clonal Heterogeneity in ER+ Breast Cancer Reveals the Proteasome and PKC as Potential Therapeutic Targets

Restoring microRNA-34a Overcomes Acquired Drug Resistance and Disease Progression in Human Breast Cancer Cell Lines via Suppressing the ABCC1 Gene

DPM2 Serve as Novel Oncogene and Prognostic Marker Transactivated by ESR1 in Breast Cancer

SOX10 Promotes the Malignant Biological Behavior of Basal-Like Breast Cancer Cells by Regulating EMT Process

Downregulation of BUBR1 Regulates the Proliferation and Cell Cycle of Breast Cancer Cells and Increases the Sensitivity of Cells to Cisplatin

The Adverse Outcome Pathway for Breast Cancer: A Knowledge Management Framework Bridging Biomedicine and Toxicology

MiRaDor Trial Marks First-Ever Joint Effort by MEDSIR and Oncoclinicas & Co in Pioneering Breast Cancer Research

6^th DNA Repair/Replication Structures and Cancer Conference

> See All Events

Junior Research Fellow – Microdroplets for Single-Cell Sensing

Research Fellow – Breast and Lung Cancer Diagnosis

PhD Positions – Cancer Cell Signaling

Animal Technician – Experimental Therapeutics

Assistant Professor Position – 3D Tissue Organoids

> See All Jobs